Table 3.
Major outcome as the need for mechanical ventilation and mortality among patients with a positive test for severe acute respiratory syndrome coronavirus-2
|
Liver function test
|
No mechanical ventilation ( n = 3205)
|
Mechanical ventilation (n = 625)
|
P
value
|
Survivor (n = 3369)
|
Non-survivors (n = 461)
|
P
value
|
| Age in yr, median (IQR) | 63.8 (48.4-77.7) | 66.3 (54.9-75.2) | 0.030 | 62.3 (47.7-74.7) | 78.1 (66.9-87.6) | < 0.001 |
| Comorbidities, n (%) | ||||||
| Chronic liver disease | 385 (12) | 80 (12.8) | 0.58 | 419 (12.4) | 46 (10) | 0.13 |
| Cardiovascular disease | ||||||
| Congestive heart failure | 662 (20.7) | 207 (33.1) | < 0.001 | 693 (20.6) | 176 (38.2) | < 0.001 |
| HT without complications | 2112 (65.9) | 463 (74.1) | < 0.001 | 2214 (65.7) | 361 (78.3) | < 0.001 |
| HT with complications | 1059 (33) | 288 (46.1) | < 0.001 | 1097 (32.6) | 250 (54.2) | < 0.001 |
| Diabetes | ||||||
| Diabetes without complications | 1161 (36.2) | 298 (47.7) | < 0.001 | 1269 (37.7) | 190 (41.2) | 0.14 |
| Diabetes with complications | 979 (30.5) | 291 (46.6) | < 0.001 | 1076 (31.9) | 194 (42.1) | < 0.001 |
| Chronic respiratory disease | 865 (27) | 200 (32) | 0.011 | 910 (27) | 155 (33.6) | 0.03 |
| Chronic neurological disease | 810 (25.3) | 223 (35.7) | < 0.001 | 835 (24.8) | 198 (43) | < 0.001 |
| CKD of any stage | 764 (23.8) | 209 (33.4) | < 0.001 | 787 (23.4) | 186 (40.3) | < 0.001 |
| Anemia | 1281 (40) | 374 (59.8) | < 0.001 | 1379 (40.9) | 276 (59.9) | < 0.001 |
| ALT, median (IQR) | 27 (18-46) | 33 (21-54) | < 0.001 | 28 (18-47) | 27 (17-45) | 0.28 |
| Normal, n (%) | 1055 (32.9) | 77 (12.3) | 1011 (30) | 121 (26.2) | ||
| 1-2 ULN, n (%) | 1065 (33.2) | 160 (25.6) | < 0.001 | 1090 (32.4) | 135 (29.3) | < 0.001 |
| > 2-5 ULN, n (%) | 786 (24.5) | 223 (35.7) | 902 (26.8) | 107 (23.2) | ||
| > 5 ULN, n (%) | 299 (9.3) | 165 (26.4) | 366 (10.9) | 98 (21.3) | ||
| AST, median (IQR) | 35 (24-54) | 44.5 (31-70) | < 0.001 | 35 (25 -54) | 45 (29 -71) | < 0.001 |
| Normal, n (%) | 1794 (58.3) | 252 (41.7) | 1856 (57.2) | 190 (43.5) | ||
| 1-2 ULN, n (%) | 946 (30.7) | 241 (39.9) | < 0.001 | 1023 (31.5) | 164 (37.5) | < 0.001 |
| > 2-5 ULN, n (%) | 283 (9.2) | 78 (12.9) | 300 (9.2%) | 61 (14.0) | ||
| > 5 ULN, < 0.001 (%) | 56 (1.8) | 33 (5.5) | 67 (2.1%) | 22 (5) | ||
| Bilirubin, median (IQR) | 0.5 (0.3-0.6) | 0.5 (0.4-0.7) | < 0.001 | 0.5 (0.3-0.6) | 0.5 (0.4-0.8) | < 0.001 |
| Normal, n (%) | 2943 (94.7) | 553 (90.8) | 3102 (94.9) | 394 (88.1) | ||
| 1-2 ULN, n (%) | 133 (4.3) | 44 (7.2) | < 0.001 | 135 (4.1) | 42 (9.4) | < 0.001 |
| > 2-5 ULN, n (%) | 23 (0.7) | 11 (1.8) | 26 (0.8) | 8 (1.8) | ||
| > 5 ULN, n (%) | 9 (0.3) | 1 (0.2) | 7 (0.2) | 3 (0.7) | ||
| ALP, median (IQR)) | 77 (61-101) | 80 (62-110) | 0.062 | 77 (61-100) | 87 (64-118) | < 0.001 |
| Normal, n (%) | 2686 (84.5) | 497 (80.7) | 2837 (85) | 346 (75.7) | ||
| 1-2 ULN, n (%) | 420 (13.2) | 105 (17) | 0.091 | 435 (13) | 90 (19.7) | < 0.001 |
| > 2-5 ULN, n (%) | 65 (2) | 13 (2.1) | 58 (1.7) | 20 (4.4) | ||
| > 5 ULN, n (%) | 7 (0.2) | 1 (0.2) | 7 (0.2) | 1 (0.2) | ||
| GGT, median (IQR) | 116 (56-199) | 144.5 (106-235.5) | 0.483 | 117 (56-199) | 180 (116.5-447.5) | 0.28 |
SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; IQR: Interquartile range; HT: Hypertension; CKD: Chronic kidney disease; ALT: Alanine aminotransferases; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; T-Bil: Total bilirubin; ULN: Upper limit of normal.